Outbreak of Mycoplasma pneumoniae–Associated Stevens-Johnson Syndrome

Daniel Olson, MD; Louise K. Francois Watkins, MD, MPH; Alicia Demirjian, MD, MMS; Xia Lin, PhD, MSPH; Christine C. Robinson, PhD, MS; Kristin Pretty, BS; Alvaro J. Benitez, BS; Jonas M. Winchell, PhD; Maureen H. Diaz, PhD, MPH; Lisa A. Miller, MD, MSPH; Teresa A Foo, MD, MPH; Melanie D. Mason, MS; Ursula L. Lauper, MA, MPH; Oren Kupfer, MD; Jeffrey Kennedy, MD; Mary P. Glodé, MD; Preeta K. Kutty, MD, MPH; Samuel R. Dominguez, MD, PhD

abstract

BACKGROUND: Stevens-Johnson syndrome (SJS) is an uncommon, sporadic disease and outbreaks are rare. In November 2013, an outbreak of SJS was identified at Children’s Hospital Colorado.

METHODS: Outbreak cases were children aged 5–21 with a discharge diagnosis of SJS admitted from September 1 to November 30, 2013. Medical charts were reviewed using standardized data collection forms. Respiratory specimens were tested for viruses and Mycoplasma pneumoniae (Mp) by polymerase chain reaction (PCR). We conducted a separate 4-year retrospective case-control study comparing hospitalized SJS cases with and without evidence of Mp infection.

RESULTS: During the outbreak, 8 children met SJS criteria. Median age was 11.5 years (range 8–16 years); 5 (63%) were boys and 5 (63%) were Mp-PCR–positive. Of the 5 PCR-positive children, none had preceding medication exposure, and all had radiographic pneumonia. All outbreak Mp isolates were macrolide susceptible. The retrospective case-control analysis showed that Mp-associated SJS episodes (n = 17) were more likely to have pneumonia (odds ratio [OR] 10.0, confidence interval [CI] 1.3–5.1), preceding respiratory symptoms (OR 30.0, CI 1.6–72.6), an erythrocyte sedimentation rate ≥35 mg/dL (OR 22.8, CI 2.1–244.9), and ≥3 affected skin sites (OR 4.5, CI 1.2–17.4) than non-Mp-associated SJS episodes (n = 23).

CONCLUSIONS: We report the largest outbreak of SJS in children, which was also predominately associated with Mp infection. Mp-associated SJS was associated with a distinct clinical presentation that included less extensive skin disease, an elevated erythrocyte sedimentation rate, and evidence of a preceding respiratory infection.

WHAT’S KNOWN ON THIS SUBJECT: Stevens-Johnson syndrome (SJS) is a rare and severe immunologic phenomenon characterized by rash and mucous membrane disease. SJS may be triggered by medications and, less commonly, by infections such as Mycoplasma pneumoniae (Mp). Outbreaks of SJS are exceedingly rare.

WHAT THIS STUDY ADDS: We describe the largest SJS outbreak reported in children, which was also Mp-associated. In the first case-control study of this disease, we identify predictors of Mp-associated SJS versus non–Mp-associated SJS, including fewer skin lesions, pneumonia, and elevated erythrocyte sedimentation rate.
Stevens-Johnson syndrome (SJS) is an immune-mediated disease characterized by a prodromal illness followed by severe mucocutaneous symptoms. SJS can result in severe morbidity from scarring of mucosal surfaces, leading to blindness as well as urethral and esophageal strictures. The case-fatality rate for SJS is ~10% in adults but may be less in children; up to 50% may develop long-term sequelae. Although the pathogenesis is incompletely understood, SJS and its more severe form, toxic epidermal necrolysis (TEN), are the result of an inflammatory response that results in keratinocyte necrosis and perivascular lymphocyte infiltration. SJS was classically ascribed to a medication hypersensitivity reaction; however, infectious etiologies, including Mycoplasma pneumoniae (Mp), are increasingly recognized as inciting agents.

SJS has an estimated incidence of 1 to 7 cases per million person-years, although pediatric rates are not well described because of a lack of published information. Epidemiologic clusters of SJS are exceptionally rare and have been associated with both medications (including mebendazole and metronidazole) and infection such as Mp. SJS attributed to Mp represents only a small fraction of overall cases, and published information about the clinical characteristics of this condition is limited to small case series.

In November 2013, physicians observed an increase in the number of children admitted to a tertiary care children’s hospital with SJS associated with Mp infection. This clinical observation prompted a formal investigation, in collaboration with the Colorado Department of Public Health and Environment and Centers for Disease Control and Prevention (CDC), to improve our understanding of the epidemiology and clinical manifestations of Mp-associated SJS. This article characterizes the largest reported pediatric SJS outbreak and describes the clinical manifestations of Mp-associated SJS.

**METHODS**

**Setting**

Children’s Hospital Colorado (CHCO) is a 553-bed, tertiary care hospital with 17,646 admissions in 2013. It is the primary children’s referral hospital for the state of Colorado, with a catchment population of 1.2 million children, and the surrounding states.

**Case Definitions**

A case of SJS during the outbreak was defined as a patient with an International Classification of Diseases, Ninth Revision (ICD-9) code for SJS, SJS-TEN, or TEN and meeting clinical criteria, including involvement of skin and at least 2 mucus membranes. Epidemiologic criteria for outbreak-associated cases of SJS were age 5 to 21 years and admission to CHCO between September 1 and November 30, 2013. The age range was selected to reflect both the patient population treated at CHCO and the population susceptible to Mp-associated SJS (extremely rare in infants, young children, and adults past middle age). The study period was selected to reflect both the long incubation period of Mp (2–4 weeks) and the time period during which clinicians reported an increase in SJS cases at CHCO. Additional hospitalized SJS cases were identified retrospectively to October 2008, when ICD-9 codes for SJS first came into use, to further characterize the spectrum of disease. SJS cases were classified according to the likelihood of Mp as the underlying etiology. To be considered a “confirmed case,” a patient required a positive Mp result by polymerase chain reaction (PCR) on a respiratory tract specimen and no alternative etiology (eg, medication effect) identified. A “probable case” required positive Mp immunoglobulin (Ig)M (with or without positive IgG) with no alternative etiology more likely. A “possible case” was defined as an SJS patient with positive Mp laboratory testing (PCR or IgM) and an alternative etiology or symptoms consistent with Mp infection (radiographic pneumonia or fever and 1 of cough, shortness of breath, or hypoxia), but laboratory testing was negative or not performed. All others were considered non-Mp-associated cases.

**Laboratory Methods**

Patients with SJS were tested for infectious etiologies at the discretion of their treating clinicians, usually at the time of hospital presentation. Testing for Mp infection at CHCO included PCR performed on throat swab specimens sent to a reference laboratory (Focus Diagnostics Inc, Cypress, CA), a respiratory pathogen PCR performed on the FilmArray (FA) system (BioFire Diagnostics, Salt Lake City, UT), and serology (IgM/IgG). FA is a US Food and Drug Administration–cleared multiplex PCR that can simultaneously detect 17 respiratory viruses and subtypes, as well as Mp, Chlamydia pneumoniae, and Bordetella pertussis in nasopharyngeal swabs; FA has been validated by the CHCO laboratory to also test nasopharyngeal wash and bronchoalveolar lavage specimens. Testing for herpes simplex virus by PCR and culture was also available.

At the time of the outbreak investigation, all available respiratory specimens from outbreak-associated SJS patients were collected from the CHCO and affiliated referral laboratories regardless of original Mp testing or test result. These specimens were sent to the Centers for Disease Control and Prevention (CDC) for confirmatory Mp PCR, culture, multiple-locus variable-number tandem-repeat analysis (MLVA) subtyping, and macrolide susceptibility profiling.
typing was used to characterize the relatedness of circulating Mp strains. In addition, stored Mp-positive specimens from non-SJS patients in the preceding 1 year were also sent to CDC for testing as a comparison group.

**Retrospective Case-Control Analysis**

A separate retrospective case-control analysis was conducted to compare clinical characteristics of Mp-associated SJS episodes with non-Mp-associated SJS episodes. Medical charts were identified by ICD-9 discharge diagnosis of SJS, SJS/TEN, or TEN and reviewed for all children admitted to CHCO between October first, 2008, and November 30th, 2013. For this analysis, Mp-associated SJS episodes included those meeting confirmed or probable criteria as defined above, based on available data. Non-Mp associated episodes were those that did not meet Mp-associated SJS criteria. Episodes meeting possible criteria as defined above were excluded from the analysis since they lacked diagnostic certainty. Mp-associated SJS episodes were compared with non-Mp-associated SJS episodes for demographic, clinical, diagnostic, and treatment variables.

**Statistical Analyses**

Clinical, laboratory, medication, treatment, and outcome data of all SJS patients were recorded on a standardized case investigation form and entered into an Epi-Info version 7.1.3.0 (Atlanta, GA) database.

A rate 300% higher than the baseline event rate was predefined as the threshold for an SJS outbreak. To determine whether the excessive observed cases in the period from September 1 to November 30, 2013, corresponded to an outbreak with such scope, cumulative sum (CUSUM) analysis was applied to all cases of SJS by month from October 1, 2008, to November 30, 2013. A threshold corresponding to an average time to a “false alarm” (also known as average run length, or ARL) of 170 months and an average time to outbreak detection of 4.5 months (ARL1) were calculated and added to the CUSUM plot. When the curve crosses the defined threshold, an outbreak is suggested.

Categorical variables were compared by using χ² or Fisher’s exact analyses. Continuous variables were compared using Wilcoxon rank-sum (Mann-Whitney U) analysis. P values <.05 were considered statistically significant. All analyses were performed by using Epi-Info version 7.1.3.0 and SAS version 9.3 (Cary, NC) software.

**Ethical Approval**

Outbreaks are reportable public health conditions in Colorado; as such, this outbreak investigation was not considered to be research that required review by an institutional review board or informed consent from the patients.

**RESULTS**

**Outbreak Investigation**

Eight SJS cases were admitted to CHCO between September 1 and November 30, 2013 (Fig 1). All had evidence of Mp infection; 5 (63%) were classified as confirmed Mp-associated SJS on the basis of positiveMp PCR results, and 3 (38%) were classified as possible Mp-associated SJS on the basis of clinical symptoms (Table 1). One child (13%) was also positive for herpes simplex virus (HSV) by PCR on an oral swab. Of 6 children tested by FA, 2 (33%) had a virus detected (1 rhino/enterovirus, 1 parainfluenza virus type 4) in addition to Mp. Both probableMp-associated SJS cases in the outbreak were taking preceding medications: 1 (13%) child was taking trimethoprim-sulfamethoxazole for a sinus infection (starting 8 days before lesion onset) and azithromycin for pertussis postexposure prophylaxis (starting 13 days before lesion onset); 1 child was taking azithromycin for pneumonia (starting 6 days before lesion onset). Three (38%) children reported household contacts with respiratory symptoms. Of the 8 children, 5 (63%) were male and the median age was 11.5 years (range 8–16 years; Table 1).

All 8 children had oropharyngeal mucositis, 7 (88%) had conjunctival involvement, and 5 (63%) had vaginal/penile involvement (Table 2). All patients had skin involvement, and the median number of sites (head, trunk, arms, legs) involved was 2.5 (range 1–4), although the severity of skin involvement overall was mild.

![FIGURE 1](https://example.com/figure1.png)

**FIGURE 1**

Mucosal disease severity varied, with 4 (50%) receiving amniotic membrane grafting to eyes, 2 (25%) requiring ICU admission, and 6 (75%) needing nasogastric feeds or total parenteral nutrition. One (13%) child did not require any of these interventions. All 8 children received azithromycin, including 2 (25%) who were put on a prolonged course (>1 year) with concern for development of bronchiolitis obliterans. All were discharged well.

The CUSUM exceeded the precalculated threshold in November 2013, indicating that an outbreak of SJS cases occurred during the study period (September 1 to November 30, 2013) (Fig 1). This finding also correlated with a large increase in Mp disease in the community.25

**Mp Characterization**

Banked Mp PCR-positive respiratory specimens were available from 48 children (including 5 children with outbreak-associated SJS and 43 with non-SJS disease) admitted to CHCO between January 1 and December 13, 2013, and were submitted to the CDC laboratory for further testing. Of these, 46 (96%) were confirmed as Mp-positive by the CDC PCR. Five MLVA types were observed among the specimens tested, including 3 among the 5 Mp-associated SJS cases: 1 of type 3-5-6-2, 2 of type 3-6-6-2, and 2 of type 4-5-7-2. Forty-three specimens (93%) were susceptible, and 3 (7%) were macrolide resistant. All Mp isolates from the SJS cases were macrolide susceptible.

**Case-Control Analysis**

Twenty-two episodes of SJS were identified as confirmed (n = 8), probable (n = 9), or possible (n = 5) Mp-associated, and 23 were identified as non-Mp-associated between October 1, 2008, and November 30, 2013 (Table 3). The 5 possible Mp-associated SJS episodes were excluded from the analysis. Of the 23 non-Mp-SJS episodes, 17 (74%) had negative Mp PCR testing, and 6 (26%) did not receive Mp PCR testing.

Demographic characteristics were similar between groups. Clinically, Mp-associated SJS episodes were significantly more likely than non-Mp-SJS episodes to have radiographic pneumonia (odds ratio [OR] 10, confidence interval [CI] 1.3–51) and to have preceding respiratory symptoms (OR 30.0, CI 1.6–72.6). Mp-associated SJS episodes had fewer skin sites involved (median 1, interquartile range [IQR] 1–4) than non-Mp-SJS episodes (median 4, IQR 2.5–4, P = .047). Mucous membranes distribution was similar between Mp-associated SJS episodes (median 3 sites, IQR 3–3) and non-Mp-SJS episodes.

### Table 1: Demographic and Exposures Characteristics Among SJS Outbreak Cases in Colorado, September to November 2013

<table>
<thead>
<tr>
<th>ID</th>
<th>Age/Gender</th>
<th>Case Category</th>
<th>Mp PCR</th>
<th>Mp IgM</th>
<th>HSV PCR</th>
<th>HSV culture</th>
<th>Preceding Medications</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>14/F</td>
<td>Possible</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>AZM, TMP/SMX</td>
</tr>
<tr>
<td>2</td>
<td>9/M</td>
<td>Confirmed (+)</td>
<td>(+)</td>
<td>(-)</td>
<td>(-)</td>
<td>(-)</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>9/M</td>
<td>Confirmed (+)</td>
<td>(+)</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>16/M</td>
<td>Confirmed (+)</td>
<td>(+)</td>
<td>NR</td>
<td>(+)</td>
<td>(-)</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>8/M</td>
<td>Possible</td>
<td>(-)</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>9/F</td>
<td>Possible</td>
<td>(-)</td>
<td>NR</td>
<td>(-)</td>
<td>(-)</td>
<td>AZM</td>
</tr>
<tr>
<td>7</td>
<td>15/F</td>
<td>Confirmed (+)</td>
<td>(+)</td>
<td>NR</td>
<td>(-)</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>14/M</td>
<td>Confirmed</td>
<td>(+)</td>
<td>(+)</td>
<td>NR</td>
<td>(-)</td>
<td></td>
</tr>
</tbody>
</table>

*AZM, azithromycin; F, female; HSV, herpes simplex virus; M, male; NR, not recorded; TMP/SMX, trimethoprim/sulfamethoxazole; —, no medications.*

### Table 2: Clinical Characteristics Among SJS Outbreak Cases in Colorado, September to November 2013

<table>
<thead>
<tr>
<th>Case Characteristic</th>
<th>All Cases</th>
<th>Confirmed Mp-Associated SJS</th>
<th>Possible Mp-Associated SJS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(n = 8)</td>
<td>(n = 5)</td>
<td>(n = 3)</td>
</tr>
<tr>
<td>Conjunctival involvement, n (%)</td>
<td>7 (88)</td>
<td>5 (100)</td>
<td>2 (67)</td>
</tr>
<tr>
<td>Oropharyngeal involvement, n (%)</td>
<td>8 (100)</td>
<td>5 (100)</td>
<td>3 (100)</td>
</tr>
<tr>
<td>Vaginal/penile involvement, n (%)</td>
<td>5 (63)</td>
<td>4 (80)</td>
<td>1 (33)</td>
</tr>
<tr>
<td>No. of skin sites involved, median (range)</td>
<td>2.5 (1–4)</td>
<td>1 (1–4)</td>
<td>3 (2–4)</td>
</tr>
<tr>
<td>Fever, n (%)</td>
<td>8 (100)</td>
<td>5 (100)</td>
<td>3 (100)</td>
</tr>
<tr>
<td>Radiographic pneumonia, n (%)</td>
<td>6 (75)</td>
<td>5 (100)</td>
<td>1 (33)</td>
</tr>
<tr>
<td>Hospital days, median (range)</td>
<td>6 (1–15)</td>
<td>6 (4–15)</td>
<td>6 (1–9)</td>
</tr>
<tr>
<td>ICU admission, n (%)</td>
<td>2 (25)</td>
<td>2 (40)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Amniotic grafting, n (%)</td>
<td>4 (50)</td>
<td>3 (60)</td>
<td>1 (33)</td>
</tr>
<tr>
<td>PCA or continuous analgesia, d, median (range)</td>
<td>0 (0–10)</td>
<td>3 (0–10)</td>
<td>0 (0–6)</td>
</tr>
<tr>
<td>NG feeds or TPN, d, median (range)</td>
<td>6.5 (0–9)</td>
<td>7 (0–10)</td>
<td>6 (0–7)</td>
</tr>
<tr>
<td>Household exposure, n (%)</td>
<td>3 (38)</td>
<td>2 (40)</td>
<td>1 (33)</td>
</tr>
<tr>
<td>Maximum ESR, median (range)</td>
<td>57 (3–122)</td>
<td>57 (18–122)</td>
<td>59.5 (3–116)</td>
</tr>
<tr>
<td>Maximum CRP, median (range)</td>
<td>3.2 (0.5–34.6)</td>
<td>23.4 (3.2–34.6)</td>
<td>1.8 (0.5–5)</td>
</tr>
</tbody>
</table>

*ESR and C-reactive protein were performed on 5 children, 3 with confirmed and 2 with possible Mp-associated SJS. IVIG, intravenous immunoglobulin; NG, nasogastric; PCA, patient-controlled analgesia; TPN, total parenteral nutrition.
episodes (median 3, IQR 2.5–3). Subjectively, the physicians caring for hospitalized SJS patients reported less severe skin disease and more severe mucositis, including ocular disease (Fig 2), among the Mp-associated SJS group. Both groups had similar duration of SJS symptoms before hospitalization (median 3 days, IQR 2–5 days).

ESR was significantly higher in Mp-associated SJS episodes (median 57 [IQR 23–105] mm/hour, reference range 0–20 mm/hour) compared with non-Mp-associated SJS episodes (18 [IQR 13–28] mm/hour, \( P = .008 \)), but C-reactive protein was similar (7.5 [IQR 2.9–10.5] mg/dL vs 6.3 [IQR 2.8–11.8] mg/dL, reference range 0–1.0 mg/dL, \( P = .730 \)). An ESR ≥35 mm/hour was strongly predictive of Mp-associated SJS (OR 22.8, CI 2.1–244.9). Treatments, duration of hospitalization (median 9 vs 11 days), ICU admissions (29% vs. 22%), and ocular amniotic membrane grafting (35% vs 32%) were similar between groups. All children were discharged well except 1 non-Mp-associated SJS child who died due to complications unrelated to SJS.

**DISCUSSION**

We describe the largest reported outbreak of SJS in children, which was predominantly associated with Mp infection. The disease was characterized by extensive mucositis, especially ocular disease, and less severe skin manifestations than non-Mp-associated SJS. In our retrospective case-control analysis of SJS hospitalizations, children with Mp-associated SJS were significantly more likely to have preceding respiratory symptoms, radiographic pneumonia, and elevated ESR than children with non-Mp-associated SJS; they also had fewer skin sites affected.

Mp-associated SJS is not well described in the literature, likely due to lack of sensitive diagnostic testing. Recently, PCR testing for Mp has begun to replace or accompany serology, allowing greater diagnostic accuracy.26 Interestingly, several case series from the 1940s may be the first descriptions of Mp-associated SJS,17,27–31 although molecular diagnostic testing was unavailable at the time. Often referred to as erythema multiforme major or exudativum, Mp-associated SJS disease, diagnosed primarily by serology, was characterized by extensive mucosal lesions and
minimal skin involvement, with an atypical “psittacosis-like” pneumonia. Furthermore, a recent, systematic review of the literature suggests that Mp-associated disease might be a clinical entity distinct from drug-induced SJS. These authors proposed renaming this entity to Mp-induced rash and mucositis due to the minimal cutaneous involvement. Our data support this finding of mucositis-predominant disease, but in contrast to the conclusion of their review, the majority of our patients had severe disease necessitating prolonged hospitalizations and surgical intervention. Outbreaks of SJS are exceedingly rare with only 2 confirmed Mp-associated SJS clusters reported (10 cases total). Although 5 children in our outbreak had positive Mp testing by PCR, all 8 met Mp-associated SJS case definitions and had additional findings supportive of an Mp etiology including radiographic pneumonia, elevated ESR, and history of exposure to household contacts with respiratory symptoms.

We offer 2 likely explanations for the recent outbreak. Our initial hypothesis was that a new Mp strain with a greater predisposition to induce SJS was circulating in the community. In support of this hypothesis, of the 5 Mp-SJS cases with available MLVA typing, 3 had a similar subtype, despite the fact that multiple MLVA subtypes were circulating in the community during this time. These subtypes, however, have not been previously associated with SJS disease and have been circulating across the United States for several years. MLVA typing may also not be a reliable measure of clonality because multiple MLVA types may circulate in a single outbreak setting. A second, more likely hypothesis is that there was a large outbreak of Mp in the community, which resulted in an increased rate of SJS due to an overall increased rate of exposure to Mp. This is supported by a community-wide investigation, which found a significant increase in atypical pneumonia diagnoses, macrolide prescriptions, and positive Mp testing. Epidemics of Mp pneumonia are known to occur in 3- to 7-year cycles, and Mp outbreaks have been previously observed in Colorado. The clinical spectrum of disease in our pediatric outbreak and retrospective case-control study was similar to previous published case series of Mp-associated SJS. Prodromal respiratory illness and fever were common. Mucositis was predominant, with multiple mucous membranes involved, including ocular lesions. We observed a less severe distribution of skin involvement in the Mp-SJS group. Mucous membrane involvement was similar between groups, but severity and distribution were more difficult to quantify. Other studies also report less severe skin manifestations and organ dysfunction in patients with Mp-associated SJS, including some who describe a Mp-associated SJS-like disease with mild or no skin lesions, referred to as Mp-associated mucositis (MPAM), atypical SJS, incomplete SJS, or Fuch syndrome. Several of our SJS cases had previous episodes of SJS, as well as previous mucositis-only episodes that did not meet our case definitions. Many experts consider these various exanthemas separate manifestations along a spectrum of SJS. In general, skin involvement is common with Mp infection, with Mp pneumonia said to be associated with rash in 3% to 33% of patients. Mp has also been cultured from blisters of patients with SJS. Several of our patients with Mp-associated SJS had severe disease, necessitating ICU admission, ventilator support, amniotic membrane grafting, and other supportive measures. Although data were limited, it was not clear that treatment with intravenous immunoglobulin (IVIG), corticosteroids, or macrolide antibiotics led to improved outcome, which is consistent with previous literature.

The significant differences between Mp-associated SJS and non-Mp-associated SJS are not surprising. Mp
is highly transmissible\textsuperscript{57} and may cause a spectrum of disease including atypical pneumonia and upper respiratory infections and may incite asthma exacerbations\textsuperscript{36,54}. ESR is known to be falsely elevated with Mp infection because of the presence of cold agglutinins\textsuperscript{58–60} and the significantly elevated ESR among Mp-SJS patients suggests its use as a potential biomarker of Mp-associated disease.

Our study has several limitations. Despite the greater accuracy of Mp PCR testing compared with serology, there remains a small risk of false-positive detection of the organism related to asymptomatic carriage or prolonged shedding (up to 4 months), both of which have been described.\textsuperscript{61} Thus, it is possible that a greater community Mp burden along with prolonged shedding led to a large number of positive tests among SJS patients who were unrelated to their SJS. However, such detections would not explain the increased number of SJS patients admitted during our outbreak window. Another limitation is that most of our SJS cases were identified retrospectively with data limited to that available in the medical records. The use of retrospective data also made it difficult to accurately quantify the severity of clinical disease. Despite some evidence of less severe skin manifestations and more severe mucositis among Mp-SJS cases in both the outbreak and retrospective case-control study, our ability to quantify these differences was limited. In addition, it is possible that during the outbreak study period, there was potential for greater awareness of Mp and SJS in the community, leading to increased testing and detection of cases. However, this increased awareness would most likely have only affected increased detection of Mp disease but not SJS because the severity of SJS in children usually necessitates admission to the hospital. The introduction of FA testing for Mp in the year preceding our outbreak may also have led to a greater case detection of Mp-SJS, although again this would likely only affect rates of Mp infection and not SJS.

**CONCLUSIONS**

We report the largest outbreak of SJS in children. We hypothesize that the SJS outbreak was due to a large community-wide outbreak of Mp.\textsuperscript{25} The spectrum of Mp-associated SJS disease was consistent with previous reports, including severe mucositis and milder skin manifestations. Several children suffered significant morbidity during their hospitalizations. The presentation of Mp-associated SJS was clinically distinct from non-Mp associated SJS and clinicians should have a high suspicion for Mp-associated SJS when disease is characterized by radiographic pneumonia, preceding respiratory symptoms, fewer skin manifestations, and elevated ESR. If future clusters of Mp-associated SJS are identified or detected, we recommend prospective collection of respiratory samples for Mp culture and typing, as well as further evaluation of treatment measures.

**ABBREVIATIONS**

CDC: Centers for Disease Control and Prevention

CHCO: Children’s Hospital Colorado

CI: confidence interval

CUSUM: cumulative sum analysis

ESR: erythrocyte sedimentation rate

FA: FilmArray

ICD-9: *International Classification of Diseases, Ninth Revision* code

Ig: immunoglobulin

IQR: interquartile range

MLVA: multiple-locus variable-number tandem-repeat analysis

Mp: *Mycoplasma pneumoniae*

OR: odds ratio

PCR: polymerase chain reaction

SJS: Stevens-Johnson syndrome

TEN: toxic epidermal necrolysis

---

FINANCIAL DISCLOSURE: Dr Glodé is a member of a Pfizer data safety monitoring board for an unrelated vaccine. Dr Robinson served on a 1-day Scientific Advisory Board to provide input into Biofire’s Gastroenteritis Pathogen polymerase chain reaction panel; Biofire markets a Respiratory Pathogen Panel that was used to detect the *Mycoplasma pneumoniae* infections described in this article. The other authors have indicated they have no financial relationships relevant to this article to disclose.

FUNDING: Dr Olson is supported by NIH/NCATS Colorado CTSI Grant Number UL1 TR001082. Contents are the authors’ sole responsibility and do not necessarily represent official NIH views. Funded by the National Institutes of Health.

POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential conflicts of interest to disclose.

REFERENCES


3. Sekula P, Dunant A, Mockenhaupt M, et al; RegiSCAR study group. Comprehensive survival analysis of


20. Robinson CC, Pretty K, Olson D, Dominguez SR. Evaluation of the FilmArray respiratory panel for detection of Mycoplasma pneumoniae and respiratory viruses in multiple specimen types. Presented at the American Society for Microbiology 30th Clinical Virology Symposium; April 2014; Daytona Beach, FL


32. Dresner E. Erythema multiforme exudativum; the Stevens-Johnson syndrome.


On page e386, under Abstract, lines 12 and 13 read: “(odds ratio [OR] 10, confidence interval [CI] 1.3–5.1), preceding respiratory symptoms (OR 30.0, CI 1.6–72.6).” This should have read: “(odds ratio [OR] 7.5, confidence interval [CI] 1.6–35.1), preceding respiratory symptoms (OR 30.0, CI 3.3–269.4).”

On page e389, under Results, lines 18 through 21 read: “pneumonia (odds ratio [OR] 10, confidence interval [CI] 1.3–5.1) and to have preceding respiratory symptoms (OR 30.0, CI 1.6–72.6).” This should have read: “pneumonia (odds ratio [OR] 7.5, confidence interval [CI] 1.6–35.1) and to have preceding respiratory symptoms (OR 30.0, CI 3.3–269.4).”

On page e390, Table 3, the OR (CI) for Pneumonia appeared as follows: “10.0 (1.3–5.1), \( P = .002 \).” It should have read “7.5 (1.6–35.1), \( P = .013 \).” The confidence intervals for the following variables in Table 3 should have read as follows, with no change in the odds ratio or statistical significance (except as noted): male, 0.4–5.9; race, nonwhite, 0.0–1.4; ethnicity, Hispanic, 0.2–3.7; fever, 0.2–25.3; conjunctival involvement, 0.2–25.3; genital involvement, 0.3–7.8; skin involvement, 0.1–1.9; recurrent SJS, 0.4–10.7; preceding URI symptoms, 3.3–269.4; household contacts with URI, OR of 2.3 instead of 2.0 and CI 0.4–12.4; ICU admission, 0.4–6.3; and amniotic graft, 0.3–4.7. A corrected version of the table is supplied here.

doi:10.1542/peds.2015-3276

**TABLE 3** Comparison of Mp-associated SJS and non-Mp-associated SJS, October 2008–November 2013

<table>
<thead>
<tr>
<th>Variable</th>
<th>Mp-SJS (n=17)</th>
<th>Non-Mp-SJS (n=23)</th>
<th>OR (CI)</th>
<th>( P ) value</th>
<th>All inpatients (n=35,964)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Demographics</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age, years, median (IQR)</td>
<td>12.7 (10.0–14.5)</td>
<td>11.7 (8.6–15.1)</td>
<td>-</td>
<td>NS</td>
<td>6.8 ± 6.9</td>
</tr>
<tr>
<td>Male, n (%)</td>
<td>12 (71)</td>
<td>14 (61)</td>
<td>1.5 (0.4–5.9)</td>
<td>NS</td>
<td>19,843 (55)</td>
</tr>
<tr>
<td>Race, non-white, n (%)</td>
<td>2 (12)</td>
<td>8 (35)</td>
<td>0.3 (0.0–1.4)</td>
<td>NS</td>
<td>3,356 (9)</td>
</tr>
<tr>
<td>Ethnicity, Hispanic, n (%)</td>
<td>4 (24)</td>
<td>6 (26)</td>
<td>0.9 (0.2–3.7)</td>
<td>NS</td>
<td>10,077 (28)</td>
</tr>
<tr>
<td><strong>Clinical</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fever (≥39.5°C), n (%)</td>
<td>16 (94)</td>
<td>20 (87)</td>
<td>2.4 (0.2–25.3)</td>
<td>NS</td>
<td>-</td>
</tr>
<tr>
<td>Oral involvement, n (%)</td>
<td>17 (100)</td>
<td>23 (100)</td>
<td>N/A</td>
<td>N/A</td>
<td>-</td>
</tr>
<tr>
<td>Conjunctival involvement, n (%)</td>
<td>16 (94)</td>
<td>20 (87)</td>
<td>2.4 (0.2–25.3)</td>
<td>NS</td>
<td>-</td>
</tr>
<tr>
<td>Genital involvement, n (%)</td>
<td>34 (192)</td>
<td>17 (74)</td>
<td>1.6 (0.3–7.8)</td>
<td>NS</td>
<td>-</td>
</tr>
<tr>
<td># mucous membranes involved, median (IQR)</td>
<td>3 (3–9)</td>
<td>3 (2.5–4)</td>
<td>-</td>
<td>NS</td>
<td>-</td>
</tr>
<tr>
<td>≥3 mucous membranes involved, n (%)</td>
<td>13 (76)</td>
<td>17 (74)</td>
<td>1.1 (0.3–4.9)</td>
<td>NS</td>
<td>-</td>
</tr>
<tr>
<td>Skin involvement, n (%)</td>
<td>13 (76)</td>
<td>21 (91)</td>
<td>0.3 (0.1–1.9)</td>
<td>NS</td>
<td>-</td>
</tr>
<tr>
<td># of skin sites involved, median (IQR)</td>
<td>1 (1–4)</td>
<td>4 (2.4–4)</td>
<td>-</td>
<td>0.047</td>
<td>-</td>
</tr>
<tr>
<td>≥3 skin sites involved, n (%)</td>
<td>12 (71)</td>
<td>8 (35)</td>
<td>4.5 (1.2–17.4)</td>
<td>0.025</td>
<td>-</td>
</tr>
<tr>
<td>Recurrent SJS, n (%)</td>
<td>4 (24)</td>
<td>3 (13)</td>
<td>2.1 (0.4–10.7)</td>
<td>NS</td>
<td>-</td>
</tr>
<tr>
<td>Pneumonia, n (%)</td>
<td>9 (53)</td>
<td>3 (13)</td>
<td>7.5 (1.6–35.1)</td>
<td>0.013</td>
<td>-</td>
</tr>
<tr>
<td>Preceding antibiotics or AEDs*, n (%)</td>
<td>0 (0)</td>
<td>9 (39)</td>
<td>1.0 (0.1–10.0)</td>
<td>&lt;0.001</td>
<td>-</td>
</tr>
<tr>
<td>Preceding URI symptoms, n (%)</td>
<td>16 (94)</td>
<td>8 (35)</td>
<td>30 (3.3–269.4)</td>
<td>&lt;0.001</td>
<td>-</td>
</tr>
<tr>
<td>Household contacts with URI, n (%)</td>
<td>5 (30)</td>
<td>4 (31)</td>
<td>2.3 (0.4–12.4)</td>
<td>NS</td>
<td>-</td>
</tr>
<tr>
<td>ESR &gt; 35 mg/dL, n (%)</td>
<td>7 (41)</td>
<td>1 (7)</td>
<td>22.8 (2.1–244.9)</td>
<td>0.007</td>
<td>-</td>
</tr>
<tr>
<td>Max CRP mg/dL, median (IQR)</td>
<td>7.5 (2.9–10.5)</td>
<td>6.3 (2.8–11.8)</td>
<td>-</td>
<td>NS</td>
<td>-</td>
</tr>
<tr>
<td><strong>Treatment</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Days hospitalized, median (IQR)</td>
<td>9 (6–12)</td>
<td>11 (8–12.5)</td>
<td>-</td>
<td>NS</td>
<td>-</td>
</tr>
<tr>
<td>NG feeding or TPN days, median (IQR)</td>
<td>7 (0–9)</td>
<td>5 (0–10)</td>
<td>-</td>
<td>NS</td>
<td>-</td>
</tr>
<tr>
<td>PCA or continuous epidural days, median (IQR)</td>
<td>0 (0–9)</td>
<td>0 (0–9)</td>
<td>-</td>
<td>NS</td>
<td>-</td>
</tr>
<tr>
<td>ICU admission, n (%)</td>
<td>5 (29)</td>
<td>5 (22)</td>
<td>1.5 (0.4–6.3)</td>
<td>NS</td>
<td>-</td>
</tr>
<tr>
<td>Amniotic graft, n (%)</td>
<td>6 (35)</td>
<td>7 (32)</td>
<td>1.2 (0.3–4.7)</td>
<td>NS</td>
<td>-</td>
</tr>
</tbody>
</table>
Outbreak of Mycoplasma pneumoniae–Associated Stevens-Johnson Syndrome
Pediatrics 2015;136:e386; originally published online July 27, 2015; DOI: 10.1542/peds.2015-0278

The online version of this article, along with updated information and services, is located on the World Wide Web at:
/content/136/2/e386.full.html
Outbreak of *Mycoplasma pneumoniae*–Associated Stevens-Johnson Syndrome


*Pediatrics* 2015;136;e386; originally published online July 27, 2015;
DOI: 10.1542/peds.2015-0278

Updated Information & Services
including high resolution figures, can be found at:
/content/136/2/e386.full.html

References
This article cites 54 articles, 11 of which can be accessed free at:
/content/136/2/e386.full.html#ref-list-1

Citations
This article has been cited by 3 HighWire-hosted articles:
/content/136/2/e386.full.html#related-urls

Post-Publication Peer Reviews (P³Rs)
One P³R has been posted to this article:
/cgi/eletters/136/2/e386

Subspecialty Collections
This article, along with others on similar topics, appears in the following collection(s):
Dermatology
/cgi/collection/dermatology_sub
Infectious Disease
/cgi/collection/infectious_diseases_sub
Epidemiology
/cgi/collection/epidemiology_sub

Errata
An erratum has been published regarding this article. Please see:
/content/136/6/1198.full.html

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
/site/misc/Permissions.xhtml

Reprints
Information about ordering reprints can be found online:
/site/misc/reprints.xhtml